Ocugen, Inc. — Form 10-Q Summary
Business context and reporting period
Ocugen is a clinical-stage biotechnology company developing gene therapies, cell therapies, biologics, and vaccines. The filing covers the unaudited three and nine months ended September 30, 2023, with comparison to the same periods in 2022. The company operates as one reporting segment and has not generated revenue from product candidates.
- Modifier gene therapy: OCU400 for retinitis pigmentosa and Leber congenital amaurosis; OCU410 for dry age-related macular degeneration; and OCU410ST for Stargardt disease.
- Regenerative medicine: NeoCart for adult knee cartilage injuries.
- Inhaled mucosal vaccines: OCU500 for COVID-19, OCU510 for seasonal influenza, and OCU520 for a combined influenza and COVID-19 vaccine.
- Biologic therapy: OCU200 for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration.
Financial condition and operating metrics
| Metric | Three months ended September 30, 2023 | Three months ended September 30, 2022 | Nine months ended September 30, 2023 | Nine months ended September 30, 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $6.3 million | $15.6 million | $30.1 million | $32.5 million |
| General and administrative expense | $9.1 million | $7.5 million | $26.8 million | $28.2 million |
| Total operating expenses | $15.4 million | $23.1 million | $56.9 million | $60.7 million |
| Loss from operations | $(15.4) million | $(23.1) million | $(56.9) million | $(60.7) million |
| Net loss | $(14.2) million | $(21.9) million | $(53.6) million | $(59.4) million |
| Net loss per share | $(0.06) | $(0.10) | $(0.22) | $(0.28) |
| Operating cash flow | Not separately provided | Not separately provided | $(50.8) million | $(43.2) million |
Because the company reported no revenue, gross margin and revenue-based operating margins are not meaningful. The nine-month operating loss represented approximately $56.9 million of operating expenses, while the company recorded $3.3 million of other income, primarily interest income and co-development activities.
- Cash and cash equivalents were $53.5 million at September 30, 2023, compared with $77.6 million at December 31, 2022. Marketable securities declined from $13.4 million to zero as securities matured.
- Total assets were $74.7 million and stockholders’ equity was $58.4 million at September 30, 2023.
- Total debt was approximately $2.8 million, including $1.3 million classified as current and $1.5 million classified as long-term. The debt principally consists of EB-5 borrowings bearing fixed interest at 4.0%.
- Net cash decreased by $24.1 million during the first nine months of 2023. Operating cash use of $50.8 million was partly offset by $5.8 million of investing cash inflows and $20.9 million of financing cash inflows.
- Capital expenditures and construction in progress increased property and equipment, net, to $14.5 million from $6.1 million at year-end 2022.
- The accumulated deficit was $266.6 million at September 30, 2023.
Material changes versus the prior comparable period
- Third-quarter net loss improved by $7.8 million, primarily because research and development expense fell by $9.3 million, partly offset by a $1.6 million increase in general and administrative expense.
- Nine-month net loss improved by $5.8 million, while operating cash use increased by $7.6 million compared with the prior-year period.
- Research and development spending declined mainly because of the termination of the COVAXIN program and lower OCU200 activity. These reductions were partly offset by increased spending on OCU400, OCU410/OCU410ST, NeoCart, and employee-related costs.
- General and administrative expense increased in the third quarter because of higher legal expenses and severance, but declined for the nine-month period because of lower pre-commercial, office-opening, and insurance costs.
- The company issued 30.0 million shares in a May 2023 public offering for net proceeds of $14.8 million and sold 4.5 million shares under its former at-the-market program for net proceeds of $5.6 million. The at-the-market agreement was terminated in February 2023.
- The company wrote off a $4.1 million advance related to COVAXIN after determining that further development in North America was no longer commercially viable. Related COVAXIN commitments are not expected to be fulfilled.
Guidance, outlook, risks, contingencies, and unusual items
- OCU400: Management intends to initiate a Phase 3 retinitis pigmentosa trial in early 2024, subject to Phase 1/2 results and FDA alignment. Expansion to Leber congenital amaurosis is expected in the second half of 2024, subject to clinical results and regulatory discussions.
- OCU410 and OCU410ST: The FDA cleared the IND applications, and the company intended to dose patients in Phase 1/2 trials by the end of 2023.
- NeoCart: The company plans to initiate a confirmatory Phase 3 trial in the second half of 2024 and is renovating a facility for GMP manufacturing. A prior Phase 3 trial did not meet its primary endpoint, although management cited favorable modified intent-to-treat results.
- OCU500: NIAID’s Project NextGen selected OCU500 for clinical trials using inhaled and nasal delivery routes, expected to begin in early 2024. The financial impact of the NIH commitment was still being assessed.
- OCU510 and OCU520: Future IND submissions may occur in 2024, but development depends on government funding.
- OCU200: The FDA placed the IND on clinical hold in April 2023 because of requests for additional chemistry, manufacturing, and controls information. A Phase 1 trial is expected in the first half of 2024 only if the hold is lifted and funding is available.
- Going concern: Management stated that the $53.5 million of cash and cash equivalents will not satisfy capital requirements for the twelve months following issuance of the financial statements. The filing therefore reports substantial doubt about the company’s ability to continue as a going concern.
- The company expects to seek additional equity or debt financing, strategic arrangements, asset sales, licensing or collaboration transactions, government funding, or other third-party funding. There is no assurance that funding will be available on acceptable terms.
- Nasdaq notified the company in May 2023 that its share price had remained below the $1.00 minimum bid requirement. On October 31, 2023, Nasdaq granted an additional compliance period through April 29, 2024. Failure to regain compliance could result in delisting.
- A securities class action was dismissed with prejudice in March 2023, but the lead plaintiff appealed. Related derivative litigation remains stayed pending resolution of the appeal. The company has not accrued a loss because an adverse outcome was not considered probable or reasonably estimable.
- Stock-based compensation expense was $7.5 million for the first nine months of 2023, and $11.5 million of related unrecognized expense remained at September 30, 2023.
Investor verification checklist
- Verify the company’s ability to raise sufficient capital before cash resources are depleted and assess potential dilution from future equity financing.
- Track quarterly cash burn, operating expenses, construction spending, and the timing of additional NeoCart and clinical-trial expenditures.
- Confirm FDA resolution of the OCU200 clinical hold and regulatory alignment for the proposed OCU400 and NeoCart Phase 3 programs.
- Evaluate whether OCU400’s preliminary Phase 1/2 results are confirmed in larger, controlled studies; the reported data are early-stage and not evidence of regulatory approval.
- Monitor the scope, timing, and funding of the NIAID OCU500 trials and the company’s ability to obtain government support for OCU510 and OCU520.
- Monitor Nasdaq bid-price compliance through April 29, 2024 and any consequences for liquidity or capital access.
- Review the pending securities appeal and derivative litigation for potential financial or reputational exposure.